Introduction
============

Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) causes coronavirus disease (COVID-19), a potentially fatal disease that is of immense global public health concern. The initial cases were reported in December 2019 in Wuhan, China.[@pvaa064-B1] Since then, there have been 3 041 764 confirmed COVID-19 patients in the world as of 27 April 2020, with a total of 211 167 deaths. The USA has the greatest number (988 189) of confirmed cases, with a total of 56 259 deaths. Most cases were diagnosed in New York (291 996), with a total of 22 668 deaths.[@pvaa064-B2]

Several studies, including a recent meta-analysis, have reported that co-existing conditions, including hypertension, cardiac diseases, cerebrovascular diseases, and diabetes, were common among patients with COVID-19 who had severe illness, were admitted to the intensive care unit (ICU), received mechanical ventilation, or died than among patients who had mild illness.[@pvaa064-B3]^,^[@pvaa064-B4]

Notably, of the most frequent comorbidities reported in these studies of patients with COVID-19, hypertension in particular is often treated with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).[@pvaa064-B5] This could theoretically result in an up-regulation of ACE2, which is an active binding target for SARS-CoV-2 virus,[@pvaa064-B6] in the epithelial cells of the lung, intestine, kidney, and blood vessels.

Although this raised concerns regarding the use of these drugs in COVID-19 patients, several animal studies presented conflicting findings regarding increased ACE2 expression due to ACEIs and ARBs, and previous human studies suggested that administration of an ACEI/ARB does not increase ACE2 expression.[@pvaa064-B7] In light of these findings and a paucity of clinical outcome studies, many professional cardiovascular and hypertension societies including the European Society of Cardiology, Italian Society of Pharmacology, International Society of Hypertension (ISH), European Society of Hypertension, Joint American Heart Association/American College of Cardiology/American Heart Failure Association, and others recommended the continued use of ACEIs/ARBs in COVID-19 patients.[@pvaa064-B8]

However, since the conception of these recommendations, several clinical studies have been conducted which evaluated the association of ACEIs and ARBs with clinical severity and mortality outcomes in COVID-19 patients. Therefore, the medical literature was systematically reviewed, and a meta-analysis was performed of the current clinical studies evaluating the safety and efficacy of ACEs and ARBs in COVID-19 patients.

Methods
=======

Literature search
-----------------

A literature search was conducted on the PubMed/MEDLINE database using keywords, i.e. 'ACE inhibitors AND COVID' and 'ARB AND COVID'. We applied search filters to include humans and English language studies published up to 1 May 2020. Additional papers of possible interest were identified by examining references of pertinent review articles and searching Google Scholar and preprint servers such as *MedRxiv* and *BioRxiv*. We included studies which evaluated clinical severity and mortality outcomes for patients with COVID-19 on an ACEI, an ARB, or both.

We excluded those studies which were *in vitro* or conducted in animal models, as well as those human studies which evaluated only ACE expression levels (*Figure [1](#pvaa064-F1){ref-type="fig"}*).

![Flow diagram for study selection.](pvaa064f1){#pvaa064-F1}

Data extraction
---------------

Information on the demographics, comorbidities, and pharmacotherapy with ACEIs, ARBs, and other drugs, clinical severity outcomes, and mortality was extracted.

Statistical analysis
--------------------

The meta-analysis for severity and mortality was conducted for four and six peer-reviewed studies, respectively, using the comprehensive meta-analysis (CMA) software version 3 (Biostat Inc., Englewood, NJ, USA). The studies were assessed for methodological quality based on the Newcastle--Ottawa Scale (NOS).[@pvaa064-B13] The NOS has eight criteria and generates scores ranging from 0 (high risk of bias) to 9 (low risk of bias). Studies with NOS scores of \>7 were regarded as high quality. Heterogeneity was assessed using the Higgin's *I*^2^ test, and the choice of fixed or random effects model was made based on the calculated heterogeneity. The publication bias was reported by using funnel plots. We reported the findings based on both a fixed and random effects model derived from the heterogeneity of the studies.

Results
=======

A total of 276 articles were found in the search. Based on the screening of titles of the articles, 178 were excluded as they did not meet the inclusion criteria. Further, abstracts of 98 articles were read and, subsequently, the full text of 41 articles were reviewed. Of these, 16 articles were shortlisted which compared the clinical and/or mortality outcomes of COVID-19 patients on an ACEI or ARB with non-users.[@pvaa064-B14] Finally, these 16 studies were included for review and, out of these, six and four studies were included in the meta-analysis of mortality and severity outcomes in COVID-19 patients on an ACEI/ARB, respectively (*Table [1](#pvaa064-T1){ref-type="table"}*).

###### 

Demographic and clinical characteristics of the patients of the included studies

  Study (month year)                 Country                       No. of patients                             Age (median, years)                                            Sex males                                HTN                                       DM                                    Other comorbidities                                                                                                                        ACEI/ARB usage
  ---------------------------------- ----------------------------- ------------------------------------------- -------------------------------------------------------------- ---------------------------------------- ----------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------
  Meng *et al.* (March 2020)         China                         417                                         64.5[\*](#tblfn2){ref-type="table-fn"} (IQR = 55.8--69.0)      24[\*](#tblfn2){ref-type="table-fn"}     42[^†^](#tblfn3){ref-type="table-fn"}     6[\*](#tblfn2){ref-type="table-fn"}   CHD: 8[\*](#tblfn2){ref-type="table-fn"}Hypothyroidism: 1[\*](#tblfn2){ref-type="table-fn"}AV block: 1[\*](#tblfn2){ref-type="table-fn"}   17[\*](#tblfn2){ref-type="table-fn"}
  Richardson *et al.* (April 2020)   USA                           5700                                        63 (IQR = 52--75)                                              3437                                     3026                                      1808                                  CAD: 595HF: 371Asthma: 479COPD: 287CKD: 268ESRD: 186                                                                                       413[^‡^](#tblfn4){ref-type="table-fn"}
  Li *et al.* (April 2020)           China                         1178                                        55.5 (IQR = 38--67)                                            545                                      362                                       203                                   CVD: 95CHD: 103HF: 21CKD: 44                                                                                                               115[\*](#tblfn2){ref-type="table-fn"}
  Liu *et al.* (March 2020)          China                         511                                         65.2 (mean) (SE = 10.7)[\*](#tblfn2){ref-type="table-fn"}      43[\*](#tblfn2){ref-type="table-fn"}     78                                        NA                                    NA                                                                                                                                         22[\*](#tblfn2){ref-type="table-fn"}
  Zhang *et al.* (April 2020)        China                         3430                                        57 (IQR = 45--65)                                              1675                                     1128                                      388                                   CHD: 178CVD: 50CKD: 52COPD: 19                                                                                                             188[\*](#tblfn2){ref-type="table-fn"}
  Feng *et al.* (April 2020)         China                         476                                         53 (IQR = 40--64)                                              271                                      113                                       49                                    CD: 38CVD: 17                                                                                                                              33[\*](#tblfn2){ref-type="table-fn"}
  Guo *et al.* (March 2020)          China                         187                                         58.50 (mean) (SD = 14.66)                                      91                                       61                                        28                                    CHD: 2CKD: 6                                                                                                                               19
  Bean *et al.* (April 2020)         UK                            205                                         62.95 (mean) (SD = 19.94)                                      106                                      105                                       62                                    CAD/HF: 30                                                                                                                                 46
  Yang *et al.* (April 2020)         China                         251                                         66 (IQR = 61--73)[\*](#tblfn2){ref-type="table-fn"}            62[\*](#tblfn2){ref-type="table-fn"}     126                                       55                                    RD: 12KD: 4CD: 35                                                                                                                          43
  Zeng *et al.* (April 2020)         China                         274                                         60 (mean) (SD = 15)                                            150                                      75                                        42                                    COPD: 15CKD: 5CD: 31CVD: 22                                                                                                                28[\*](#tblfn2){ref-type="table-fn"}
  Ip *et al.* (April 2020)           USA                           3017                                        NA                                                             NA                                       1584                                      NA                                    NA                                                                                                                                         460
  Yan *et al.* (April 2020)          China                         49 277                                      48.75[^§^](#tblfn5){ref-type="table-fn"} (mean) (SD = 14.19)   311[^§^](#tblfn5){ref-type="table-fn"}   137                                       60                                    CD/CVD: 16                                                                                                                                 58
  Mancia *et al.* (May 2020)         Italy                         37 031                                      68 (mean) (SD = 13)                                            23 329                                   NA                                        NA                                    CD: 8570RD: 2367KD: 1129                                                                                                                   15 375
  Mehra *et al.* (May 2020)          Asia, Europe, North America   8910                                        49 (mean) (SD = 16)                                            5346                                     2346                                      1272                                  COPD: 225                                                                                                                                  1326
  Reynolds *et al.* (May 2020)       USA                           12 594[^¶^](#tblfn6){ref-type="table-fn"}   49 (IQR = 34 --63)                                             5226                                     4357                                      2271                                  Prior MI: 524HF: 784CKD: 1214COPD: 1833                                                                                                    1110
  Dauchet *et al.* (May 2020)        France                        288[\*\*](#tblfn7){ref-type="table-fn"}     NA                                                             179                                      105[^††^](#tblfn8){ref-type="table-fn"}   40                                    RD: 31KD: 9CD: 48                                                                                                                          62[^‡‡^](#tblfn9){ref-type="table-fn"}

HTN, hypertension; DM, diabetes mellitus; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IQR, interquartile range; CHD, coronary heart disease; AV block, atrioventricular block; CAD, coronary artery disease; HF, heart failure; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; CVD, cerebrovascular disease; SE, standard error; NA, not applicable; CD, cardiovascular disease; SD, standard deviation; RD, respiratory disease; KD, kidney disease, MI, myocardial infarction.

Reported for hypertensive patients.

Nine out of total 51 hypertensive patients were excluded in subsequent analysis because they were not on any antihypertensive drugs during hospitalization.

Home medication reconciliation information was available for 2411 of the 2634 patients who were discharged or who died by the study end.

Calculated for 610 COVID 19 patients out of total of 49 277.

Patients tested for COVID-19.

Patients aged over 35 years suspected of or diagnosed with COVID-19.

Patients on antihypertensive treatment.

Reported for COVID-19-positive patients (187 out of 288 suspected of or diagnosed patients).

All the included studies compared clinical severity-related outcomes in COVID-19 patients on an ACEI or ARB with non-users. However, there was non-uniformity in the definition of the severe outcomes amongst the studies. THe studies by Meng *et al*., Li *et al*., Liu *et al*., Feng *et al*., and Yang *et al.* were all conducted in China and defined clinical severity of COVID 19 based on guidelines established by the National Health Commission of the People's Republic of China (7th edition).[@pvaa064-B30] Of these, Meng *et al.*, Liu *et al.*, and Feng *et al.* reported that patients on an ACEI/ARB had lower rates of severe outcomes as compared with non-users, whereas Li *et al.* and Yang *et al.* reported equivalent results. Additionally, a study in France by Dauchet *et al.* also reported equivalent results. However, none of these studies performed adjustments for covariates or a matched analysis[@pvaa064-B14]^,^[@pvaa064-B20]^,^[@pvaa064-B22]^,^[@pvaa064-B27] (*Table [2](#pvaa064-T2){ref-type="table"}*). Based on the NOS, Meng *et al*., Richardson *et al*., Li *et al*., Feng *et al*., Guo *et al*., Yang *et al*., and Zeng *et al*. were lower quality studies, whereas the studies conducted by Liu *et al*., Zhang *et al*, Bean *et al*., Yan *et al*., Mancia *et al*., Mehra *et al*., and Reynolds *et al.* had high methodological quality.

###### 

Comparison of clinical severity and mortality outcomes in COVID-19 patients on an ACEI and/or ARB vs. non-users

  Study (month year)                          No. of patients on an ACEI                  No. of patients on an ARB                    No. of patients on ACEI/ARB                 No. of patients not on an ACEI/ARB          Severe outcomes on ACEI/ARB vs. no ACEI/ARB                                                                                                                                                                                                                                              Mortality on an ACEI/ARB vs. no ACEI/ARB
  ------------------------------------------- ------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Meng *et al.* (March 2020)                  2                                           15                                           17                                          25 (HTN)                                    23.5% vs. 48%[\*](#tblfn11){ref-type="table-fn"}                                                                                                                                                                                                                                         0% vs. 4%
  Richardson *et al.* (April 2020)            168                                         245                                          413                                         953                                         Ventilation19.6% (ACEI) vs. 18.8% (ARB) vs. 12.8% (no ACEI/ARB)ICU21.4% (ACEI) vs. 20.8% (ARB) vs. 14.8% (no ACEI/ARB)                                                                                                                                                                   32.7% (ACEI) vs. 30.6% (ARB) vs. 26.7% (no ACEI/ARB)
  Li *et al.* (April 2020)                    NA                                          NA                                           115                                         247                                         49.6% vs/ 47%[\*](#tblfn11){ref-type="table-fn"}*P*-value = 0.65                                                                                                                                                                                                                         18.3% vs 22.7%*P*-value = 0.34
  Liu *et al.* (March 2020) (HTN, *n* = 78)   3                                           19                                           22                                          17[^†^](#tblfn12){ref-type="table-fn"}      33.3% (ACEI) vs. 31.5% (ARB) vs. 58.8% (no use)[\*](#tblfn11){ref-type="table-fn"}OR[^‡^](#tblfn13){ref-type="table-fn"} = 0.567 (95% CI = 0.109--2.948), *P*-value = 0.566 (ACEI) vs. OR[^‡^](#tblfn13){ref-type="table-fn"} = 0.537 (95% CI = 0.248--1.162), *P*-value = 0.179 (ARB)   NA
  Zhang *et al.* (April 2020)                 31[^§^](#tblfn14){ref-type="table-fn"}      157[^§^](#tblfn14){ref-type="table-fn"}^.^   174[^¶^](#tblfn15){ref-type="table-fn"}     348[^¶^](#tblfn15){ref-type="table-fn"}     Invasive ventilation5% vs 5.4%Absolute difference = 3.5 (95% CI = 1.4--5.6), *P*-value = 0.86Septic shockHR = 0.32 (95% CI = 0.13--0.80), *P*-value = 0.01ARDSHR = 0.65 (95% CI = 0.41--1.04), *P*-value= 0.07                                                                           Adjusted HR = 0.37 (95% CI = 0.15--0.89), *P*-value = 0.03
  Feng *et al.* (April 2020)                  8                                           27                                           33                                          62[\*\*](#tblfn16){ref-type="table-fn"}     Severe[\*](#tblfn11){ref-type="table-fn"}12.5% (ACEI) vs. 7.4% (ARB) vs. 6.1% (ACEI/ARB) vs. 19.4% (other regimens)Critical[\*](#tblfn11){ref-type="table-fn"}0% (ACEI) vs. 7.4% (ARB) vs. 6.1% (ACEI/ARB) vs. 24.3% (other regimens)                                                    NA
  Guo *et al.* (March 2020)                   NA                                          NA                                           19                                          168                                         Use of ACEIs/ARBs was higher in patients with elevated TnT levels (21.1% vs. 5.9%)                                                                                                                                                                                                       36.8% vs. 25.6%
  Bean *et al.* (April 2020)                  37                                          9                                            46                                          159                                         13.5% (ACEI) vs. 44.4% (ARB) vs. 27.7% (no ACEI/ARB)[^††^](#tblfn17){ref-type="table-fn"}                                                                                                                                                                                                NA
  Yang *et al.* (April 2020)                  NA                                          NA                                           43                                          83                                          Severe[\*](#tblfn11){ref-type="table-fn"}25.6% vs. 19.3%Critical[\*](#tblfn11){ref-type="table-fn"}9.3% vs. 22.9%; *P*-value = 0.061                                                                                                                                                     4.7% vs. 13.3%; *P*-value = 0.216
  Zeng *et al.* (April 2020)                  NA                                          NA                                           28                                          47                                          Severe pneumonia[^‡‡^](#tblfn18){ref-type="table-fn"}54% vs. 32%                                                                                                                                                                                                                         7% vs. 11%
  Ip *et al.* (April 2020)                    277                                         219                                          460                                         669                                         NA                                                                                                                                                                                                                                                                                       27%, *P*-value = 0.001 (ACEI) vs. 33%, *P*-value = 0.12 (ARB) vs. 30% (ACEI/ARB) vs. 39% (no ACEI/ARB)
  Yan *et al.* (April 2020)                   5                                           53                                           58                                          NA                                          OR = 1.23 (95% CI = 0.19--7.93), *P*-value = 0.826 (ACEI)[^§§^](#tblfn19){ref-type="table-fn"}OR = 0.77 (95% CI = 0.36--1.63), *P*-value = 0.495 (ARB)[^§§^](#tblfn19){ref-type="table-fn"}                                                                                              NA
  Mancia *et al.* (May 2020)                  8071                                        7304                                         15 375                                      NA                                          Mild to moderateOR = 0.97 (0.88--1.07) (ACEI vs. no ACEI)OR = 0.96 (0.87--1.07) (ARB vs. no ARB)Critical or fatalOR = 0.91 (0.69--1.21) (ACEI vs. no ACEI)OR = 0.83 (0.63--1.10) (ARB vs no ARB)                                                                                         Included with critical or fatal outcomes
  Mehra *et al.* (May 2020)                   770                                         556                                          1326                                        NA                                          NA                                                                                                                                                                                                                                                                                       OR = 0.33 (95% CI = 0.20--0.54) (ACEI vs. no ACEI)OR = 1.23 (95% CI = 0.87--1.74) (ARB vs. no ARB)
  Reynolds *et al.* (May 2020)                627                                         664                                          1110                                        1101                                        23.9% vs. 25.9% (ACEI vs. no ACEI)[^¶¶^](#tblfn20){ref-type="table-fn"}24.4% vs. 25.8% (ARB vs. no ARB)[^¶¶^](#tblfn20){ref-type="table-fn"}24.8% vs. 24.9% (ACEI/ARB vs. no ACEI/ARB)[^¶¶^](#tblfn20){ref-type="table-fn"}                                                              Included with severe outcomes
  Dauchetc*et al.* (May 2020)                 31[\*\*\*](#tblfn21){ref-type="table-fn"}   31[\*\*\*](#tblfn21){ref-type="table-fn"}    62[\*\*\*](#tblfn21){ref-type="table-fn"}   23[\*\*\*](#tblfn21){ref-type="table-fn"}   SPR1 (95% CI)1.17 (0.83--1.67) (ACEI)1.17 (0.83--1.67) (ARB)1.23 (0.82--1.86) (no ACEI/ARB)                                                                                                                                                                                              NA

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HTN, hypertension; ICU, intensive care unit; NA, not applicable; OR, odds ratio; CI, confidence interval; HR, hazard ratio; ARDS, acute respiratory distress syndrome; TnT, troponin T; SPR1, standardized prevalence ratio (R1, North of France population reference).

Severity of COVID-19 patients according to the National Health Commission of the People's Republic of China guidelines.

Not on any antihypertensive drug.

Odds ratio with reference to patients not on any antihypertensive.

Before matching.

After matching.

Other regimens.

Primary endpoint being death or transfer to a critical care unit for organ support within 7 days of symptom onset.

The criteria were based on the American Thoracic Society and Infectious Diseases Society of America.

Odds ratio of severe vs. non-severe.

Severe COVID-19 was defined as admission to the intensive care unit, the use of non-invasive or invasive mechanical ventilation, or death.

Reported for COVID-19-positive patients (187 out of 288 suspected of or diagnosed patients).

Richardson *et al*. and Zhang *et al.* compared the rates of invasive ventilation and found that they were slightly higher or equivalent in patients on an ACEI/ARB as compared with non-users, respectively. In addition, Richardson *et al.* also reported slightly higher rates of ICU admissions in patients on an ACEI (21.4%) and an ARB (20.8%) as compared with non-users (14.8%). Zhang *et al.* reported that the patients on an ACEI/ARB had lower rates of septic shock \[hazard ratio (HR) = 0.32, *P*-value = 0.01\] and acute respiratory distress syndrome (ARDS) (HR = 0.65, *P*-value = 0.07) as compared with non-users.[@pvaa064-B15]^,^[@pvaa064-B21] On the other hand, Guo *et al.* found that patients with elevated troponin T (TnT) levels were more frequently on an ACEI/ARB (21.1% vs. 5.9%) (25) (*Table [2](#pvaa064-T2){ref-type="table"}*).

In a pooled analysis of four peer-reviewed studies, there was a statistically non-significant association of an ACEI/ARB with lower odds of developing severe disease vs. non-users (OR = 0.81, 95% CI 0.41--1.58, *I*^2^ = 50.52, *P*-value = 0.53) (*Figures [2](#pvaa064-F2){ref-type="fig"}* and [*3*](#pvaa064-F3){ref-type="fig"}).
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Mortality outcomes were assessed in nine studies, namely Meng *et al.*, Richardson *et al.*, Li *et al.*, Zhang *et al.*, Guo *et al.*, Yang *et al.*, Zeng *et al.*, Ip *et al.*, and Mehra *et al*. In addition, Bean *et al.* looked at composite primary endpoints including death or transfer to critical care for organ support within 7 days of symptom onset. Mancia *et al.* reported patients who received assisted ventilation or died as having a critical or fatal infection. Meng *et al.*, Li *et al.*, Yang *et al.*, Zeng *et al.*, and Ip *et al.* reported lower rates of mortality in ACEI/ARB users vs. non-users in an unadjusted analysis. Zhan *et al.* performed matching and an adjusted analysis of 522 patients in which they found that the rate of mortality was statistically significantly lower in patients on an ACEI/ARB as compared with non-users (HR = 0.37, *P*-value = 0.03\]. Mehr *et al.* reported lower mortality in patients on an ACEI vs. no ACEI (OR = 0.33, 95% CI = 0.20--0.54). Similarly, Bean *et al.* found lower rates of their primary endpoint of death or critical care transfer in patients on ACEIs as compared with non-users (13.5% vs. 27.7%). Mancia *et al.* found a lower rate of critical or fatal outcomes in patients on an ACEI vs. no ACEI (OR = 0.91, 95% CI 0.69--1.21) and in patients on an ARB vs. no ARB (OR = 0.83, 95% CI 0.63--1.10). Similarly, Reynolds *et al.* found a slightly lower rate of severe outcomes which included admission to the ICU, the use of non-invasive or invasive mechanical ventilation, or death in patients on an ACEI/ARB (24.8%) vs. no ACEI/ARB (24.9%)[@pvaa064-B14]^,^[@pvaa064-B15]^,^[@pvaa064-B17]^,^[@pvaa064-B21]^,^[@pvaa064-B22]^,^[@pvaa064-B25] (*Table [2](#pvaa064-T2){ref-type="table"}*).

On the contrary, Guo *et al.* and Richardson *et al.* reported higher rates of mortality in patients on ACEIs/ARB as compared with non-users. Richardson *et al.* included 168 hypertensive patients on ACEIs, 245 on ARBs, and 953 patients on neither an ACEI nor an ARB, and reported 32.7, 30.6, and 26.7% mortality rates, respectively[@pvaa064-B15]^,^[@pvaa064-B25] (*Table [2](#pvaa064-T2){ref-type="table"}*).

In a pooled analysis of six peer-reviewed studies, there was a statistically non-significant association of ACEIs/ARBs with lower odds of mortality as compared with non-users (OR = 0.86, 95% CI = 0.53--1.41, *I*^2^ = 79.12, *P*-value = 0.55) (*Figures [4](#pvaa064-F4){ref-type="fig"}* and [*5*](#pvaa064-F5){ref-type="fig"}) The sensitivity of the pooled results of clinical severity and mortality outcomes to the removal of each study is reported in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figures S1--S4](#sup1){ref-type="supplementary-material"}*.

![Forest plot depicting meta-analysis of mortality outcomes in COVID-19 patients on an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB).](pvaa064f4){#pvaa064-F4}

![Funnel plot depicting publication bias for studies evaluating mortality outcomes in COVID-19 patients on an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB).](pvaa064f5){#pvaa064-F5}

Discussion
==========

Despite the worldwide implementation of public health measures such as social distancing, contact tracing, and mass testing to aid in the control of COVID-19, the global cases have risen to \>3 million, and \>200 000 patients had lost their lives by 27 April 2020,[@pvaa064-B2]^,^[@pvaa064-B31] which further requires attention. Several studies have reported increased rates of COVID-19-associated mortality in patients with significant comorbidities such as hypertension, cardiovascular disease, chronic kidney disease, or heart failure.[@pvaa064-B3]^,^[@pvaa064-B4] Although ACEIs and ARBs are commonly prescribed to treat some of these comorbidities, the fact that the ACE2 receptor is the main binding site for entry of SARS-CoV-2 caused concerns regarding the use of ACEIs and ARBs in such patients.[@pvaa064-B5]^,^[@pvaa064-B32]

Several evidence-based consensus and position statements were formulated by various cardiovascular and hypertension societies which recommended continued use of ACEIs and ARBs in COVID-19 patients, citing the lack of any contrary clinical evidence.[@pvaa064-B8] Since then, however, several clinical studies have evaluated the association of ACEIs and ARBs in COVID-19 patients and comorbidities.

It is imperative to accurately predict clinical outcomes of COVID-19 patients, especially those with comorbidities and taking an ACEI or ARB, to decide whether to continue or switch to another medication. However, there were conflicting findings reported in several studies, as Meng *et al.*, Liu *et al.*, Feng *et al.*, Zhan *et al.*, Mancia *et al.*, and Reynolds *et al.* reported that patients on an ACEI or an ARB had lower rates of severe outcomes, whereas Richardson *et al.* and Zhang *et al.* reported higher or equivalent rates of invasive ventilation, respectively. In addition, Richardson *et al.* reported a higher rate of ICU admissions in patients on ACEIs/ARBs as compared with non-users, and Guo *et al.* found that patients on ACEIs/ARBs had higher rates of cardiovascular disease and elevated TnT levels. It is pertinent to note that none of the above studies performed adjustment for covariates or matching for analysis, undermining the statistical strength of their results to a certain extent.[@pvaa064-B14]^,^[@pvaa064-B15]^,^[@pvaa064-B17]^,^[@pvaa064-B19]^,^[@pvaa064-B21]^,^[@pvaa064-B23] However, Zhang *et al.* did perform matching and an adjusted analysis of 522 patients in which they found slightly higher rates of ICU admissions in patients on an ACEI (21.4%) or an ARB (20.8%) as compared with non-users (14.8%).[@pvaa064-B21] In our random effects meta-analysis, a pooled analysis of four peer-reviewed studies conducted in China revealed that there was a statistically non-significant association (OR = 0.81, 95% CI 0.41--1.58, *I*^2^=50.52, *P*-value = 0.53) of ACEI/ARB use with lower odds of developing severe disease defined as per the Chinese COVID-19 guidelines in patients on ACEIs/ARBs vs. non-users (*Figures [2](#pvaa064-F2){ref-type="fig"}* and [*3*](#pvaa064-F3){ref-type="fig"}).

Similarly, there were also conflicting results on the rate of mortality reported by the various clinical studies. Meng *et al.*, Li. *et al.*, Zhang *et al.*, Yang *et al.*, Zeng *et al.*, and Ip *et al.* reported lower rates of mortality in ACEI/ARB users vs. non-users. whereas Guo *et al.* and Richardson *et al.* reported higher rates of mortality in patients on ACEIs/ARBs as compared with non-users.[@pvaa064-B14]^,^[@pvaa064-B15]^,^[@pvaa064-B21]^,^[@pvaa064-B22]^,^[@pvaa064-B25]^,^[@pvaa064-B27] Zhang *et al.* again performed matching and adjustment in assessing the mortality outcomes, strengthening their conclusions regarding safety of ACEI/ARB use; however, a large sample size study conducted in New York in \>1000 COVID-19 patients by Richardson *et al.* raised concerns of worse mortality outcomes with ACEI/ARB use and cannot be overlooked.[@pvaa064-B15]^,^[@pvaa064-B21] In a pooled analysis of six peer-reviewed studies, there was a statistically non-significant association of ACEI/ARB use with lower odds of mortality as compared with non-users (OR = 0.86, 95% CI = 0.53--1.41, *I*^2^ = 79.12, *P*-value = 0.55) (*Figures [4](#pvaa064-F4){ref-type="fig"}* and [*5*](#pvaa064-F5){ref-type="fig"}).

Several hypotheses have been put forward explaining the positive and negative aspects of ACEI/ARB administration in COVID-19 patients. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEIs/ARBs, suggesting that the use of an ACEI might be protective against respiratory complications. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are up-regulated, which may lead to severe pneumonia, increasing the risk of severe outcomes and mortality.[@pvaa064-B33] Individuals with ACE2 polymorphisms have an increased genetic predisposition for an increased risk of SARS-CoV-2 infection and may have harmful effects of ACEIs/ARBs.[@pvaa064-B34] This aspect is worth considering and needs to be evaluated in future studies.

To the best of our knowledge, this systematic review is a comprehensive exploration and analysis of existing literature in this topic to date. Our review has limitations in its rigour due to the scarce existing data and diverse study types available. The rapidly emerging knowledge base of COVID-19 presents the possibility that a few studies (particularly unpublished/under peer review) remain uncaptured. However, we have tried our best to mitigate this by allowing broad search terms and by including many databases and repositories. We have also tried to comprehensively review and analyse the existing data.

Considering the inconsistent clinical studies and conflicting hypotheses, it is essential to evaluate the clinical outcomes in COVID-19 patients on ACEIs/ARBs in future large studies, particularly randomized controlled trials, and additionally evaluate the association of clinical outcomes with ACE2 polymorphisms. Based on this, there are ongoing trials studying the effect of losartan (an ARB) in patients with COVID-19 in outpatient and inpatient settings (NCT04311177 and NCT04312009).[@pvaa064-B35]^,^[@pvaa064-B36]

Conclusion
==========

It is concluded that ACEIs and ARBs should be continued in COVID-19 patients, reinforcing the recommendations made by several medical societies. Additionally, the individual patient factors such as ACE2 polymorphisms which might confer higher risk of adverse outcomes need to be evaluated further.
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